Patents by Inventor Kurt Laumen

Kurt Laumen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for early sacubitril intermediates
    Patent number: 10774036
    Abstract: The invention relates to a new enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: September 15, 2020
    Assignee: Novartis AG
    Inventors: Florian Karl Kleinbeck-Riniker, Tobias Kapferer, Hongyong Kim, Jie Ku, Kurt Laumen, Yunzhong Li, Wei Peng, Thomas Ruch, Thierry Schlama, Yao Yang
  • NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES
    Publication number: 20190359554
    Abstract: The invention relates to a new enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone.
    Type: Application
    Filed: December 20, 2017
    Publication date: November 28, 2019
    Inventors: Florian Karl KLEINBECK-RINIKER, Tobias KAPFERER, Hongyong KIM, Jie KU, Kurt LAUMEN, Yunzhong LI, Wei PENG, Thomas RUCH, Thierry SCHLAMA, Yao YANG
  • Chemical process for preparing spiroindolones and intermediates thereof
    Patent number: 9598712
    Abstract: The present invention relates to processes and intermediates useful for the manufacture of spiroindolone compounds such as (1?R,3?S)-5,7?-dichloro-6?-fluoro-3?-methyl-2?,3?,4?,9?-tetrahydrospiro[indoline-3,1?-pyrido[3,4-b]indol]-2-one and salts and hydrates and solvates thereof.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: March 21, 2017
    Assignee: Novartis AG
    Inventors: Michael Crowe, Michael Foulkes, Giancarlo Francese, Dominique Grimler, Ernst Kuesters, Kurt Laumen, Yunzhong Li, Changxue Lin, Jovana Nazor, Thomas Ruch, Derek Smith, Shiwei Song, Shangjun Teng
  • Chemical Process for Preparing Spiroindolones and Intermediates Thereof
    Publication number: 20150045562
    Abstract: The present invention relates to processes and intermediates useful for the manufacture of spiroindolone compounds such as (1?R,3?S)-5,7?-dichloro-6?-fluoro-3?-methyl-2?,3?,4?,9?-tetrahydrospiro[indoline-3,1?-pyrido[3,4-b]indol]-2-one and salts and hydrates and solvates thereof.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 12, 2015
    Applicant: Novartis AG
    Inventors: Michael Crowe, Michael Foulkes, Giancarlo Francese, Dominique Grimler, Ernst Kuesters, Kurt Laumen, Yunzhong Li, Changxue Lin, Jovana Nazor, Thomas Ruch, Derek Smith, Shiwei Song, Shangjun Teng
  • Macrocyclic compounds useful as BACE inhibitors
    Patent number: 8039455
    Abstract: The invention relates to novel macrocyclic compounds of the formula in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: October 18, 2011
    Assignee: Novartis AG
    Inventors: Claudia Betschart, Manuel Koller, Kurt Laumen, Andreas Lerchner, Rainer Machauer, Clive McCarthy, Marina Tintelnot-Blomley, Siem Jacob Veenstra
  • CYCLOPENTENE DIOL MONOACETATE DERIVATIVES
    Publication number: 20100041918
    Abstract: A process for the preparation of organic compounds of formula (I), wherein R1 is as described herein.
    Type: Application
    Filed: November 5, 2007
    Publication date: February 18, 2010
    Inventor: Kurt Laumen
  • Macrocyclic Lactams and Pharmaceutical Use Thereof
    Publication number: 20100022500
    Abstract: The present invention relates to novel macrocyclic compounds of the formula wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: September 25, 2009
    Publication date: January 28, 2010
    Inventors: Yves AUBERSON, Claudia Betschart, Ralf Glatthar, Kurt Laumen, Rainer MacHauer, Marina Tintelnot-Blomley, Thomas J. Troxler, Siem Jacob Veenstra
  • MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS
    Publication number: 20090312370
    Abstract: The invention relates to novel macrocyclic compounds of the formula in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
    Type: Application
    Filed: July 20, 2007
    Publication date: December 17, 2009
    Inventors: Kurt Laumen, Rainer Machauer, Marina Tintelnot-Blomley, Siem Jacob Veenstra
  • Macrocyclic lactams and pharmaceutical use thereof
    Patent number: 7612055
    Abstract: The present invention relates to novel macrocyclic compounds of the formula wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: November 3, 2009
    Assignee: Novartis AG
    Inventors: Yves Auberson, Claudia Betschart, Ralf Glatthar, Kurt Laumen, Rainer Machauer, Marina Tintelnot-Blomley, Thomas J. Troxler, Siem Jacob Veenstra
  • MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS
    Publication number: 20090029960
    Abstract: The invention relates to novel macrocyclic compounds of the formula in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
    Type: Application
    Filed: December 28, 2006
    Publication date: January 29, 2009
    Inventors: Claudia Betschart, Manuel Koller, Kurt Laumen, Andreas Lerchner, Rainer Machauer, Clive McCarthy, Marina Tintelnot-Blomley, Siem Jacob Veenstra
  • Macrocyclic lactams and pharmaceutical use thereof
    Publication number: 20070072792
    Abstract: The present invention relates to novel macrocyclic compounds of the formula wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 4, 2004
    Publication date: March 29, 2007
    Inventors: Yves Auberson, Claudia Betschart, Ralf Glatthar, Kurt Laumen, Rainer Machauer, Marina Tintelnot-Blomley, Thomas Troxler, Siem Veenstra
  • Biocatalysts with amine acylase activity
    Patent number: 6235516
    Abstract: The invention belongs to the field of biotechnology. It concerns a biocatalyst, i.e. a dead or living microorganism or a polypeptide, preferably in isolated form, which exhibits acylase enzymatic activity without lipase- or esterase-activity. The biocatalyst is capable of stereoselectively hydrolysing a racemic acylamide which has an aliphatic acyl residue and which is not a derivative of a natural amino acid.
    Type: Grant
    Filed: November 12, 1998
    Date of Patent: May 22, 2001
    Assignee: Novartis AG
    Inventors: Oreste Ghisalba, Matthias Kittelmann, Kurt Laumen, Paula Walser-Volken
  • Chiral synthesis units from prochiral glycerol
    Patent number: 4922001
    Abstract: Differentiation of the two enantiotopic groups in prochiral glycerol derivatives gives chiral molecules directly, which in turn are easily converted either into the S-series or into the R-series by selective manipulation of the functional groups.
    Type: Grant
    Filed: July 20, 1987
    Date of Patent: May 1, 1990
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Manfred Schneider, Kurt Laumen, Detlef Breitgoff, Dieter Wullbrandt, Merten Schilingmann, Reinhold Keller
  • Process for the preparation of (1S, 4R)-4-hydroxy-2-cyclopentenyl esters
    Patent number: 4618690
    Abstract: Optically pure (1S, 4R)-4-hydroxy-2-cyclopentyl ester of the formula ##STR1## in which Ac is an aliphatic acyl radical having 1 to 18 carbon atoms,is produced by contacting a meso such as porcine liver esterase. The products are useful in synthesizing cyclopentanoid products such as brefeldin A, sesquiterpenes and prostaglandins.
    Type: Grant
    Filed: May 15, 1985
    Date of Patent: October 21, 1986
    Assignee: Bayer Aktiengesellschaft
    Inventors: Manfred Schneider, Kurt Laumen